To join this case, fill out the form below
Seagen Inc. Investigation
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Seagen Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Seagen Inc. (“Seagen” or the “Company”) (NASDAQ: SGEN) in connection with the proposed acquisition of the Company by Pfizer Inc.(NYSE: PFE).  Under the terms of the merger agreement, the Company’s shareholders will receive $229.00 in cash for each share of Seagen owned.  The transaction is valued at approximately $43 billion.

Weiss Law is investigating whether (i) Seagen’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $229.00 per share merger consideration adequately compensates Seagen’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Other Cases

January 23, 2024

Inhibrx, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Inhibrx, Inc. (“Inhibrx” or the “Company”)(NASDAQ: INBX), in connection with its acquisition by Aventis Inc. Under the merger agreement, the Company’s shareholders will receive: (i) $30.00 per share; (ii) one contingent value right (“CVR”) per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone; and (iii) one SEC-registered, publicly listed, share of New Inhibrx per every four shares of Inhibrx common stock held.

Join Case →

January 16, 2024

Carrols Restaurant Group, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Carrols Restaurant Group, Inc. (“Carrols” or the “Company”) (NASDAQ: TAST), in connection with its acquisition by Restaurant Brands International Inc. (NYSE: QSR). Under the merger agreement, the Company’s shareholders will receive $9.55 per share. The transaction is valued at approximately $1.0 billion.

Join Case →

January 10, 2024

Juniper Networks, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Juniper Networks, Inc. (“Juniper” or the “Company”) (NYSE: JNPR), in connection with its acquisition by Hewlett Packard Enterprise Company (NYSE: HPE). Under the merger agreement, the Company’s shareholders will receive $40.00 per share. The transaction is valued at approximately $14 billion.

Join Case →

Where to find us?

new york

305 Broadway, 7th FI
New York, NY 10007
(212) 682-3025

california

8383 Wilshire Blvd., Suite 935
Beverly Hills, CA 90211
(310) 208-2800

georgia

476 Hardendorf Ave. NE
Atlanta, GA 30307
(404) 692-7910

NEW JERSEY

4 Brighton Rd, Suite. 204
Clifton, NJ 07012

Copyright 2022 Weiss Law. All rights reserved

Attorney AdvertisingLegal

Design by Cramdyn